Clonidine Transdermal Patch Half-Life
The elimination half-life of clonidine after removal of the transdermal patch (Catapres-TTS) is approximately 20 hours 1.
Pharmacokinetic Profile
After you remove the Catapres-TTS patch, clonidine plasma concentrations decline slowly with a half-life of approximately 20 hours 1. This is notably longer than the elimination half-life seen with intravenous or oral administration, which ranges from 12-16 hours in patients with normal renal function 1.
Key Pharmacokinetic Details:
- Steady-state achievement: Occurs within 3 days after transdermal application 1
- Bioavailability: Approximately 60% from the transdermal system 1
- Distribution half-life: About 20 minutes (IV administration) 1
- Elimination half-life (IV/oral): 12-16 hours in normal renal function 1
- Elimination half-life (transdermal, after patch removal): Approximately 20 hours 1, 2
Clinical Implications
The prolonged 20-hour elimination half-life after patch removal has important clinical consequences:
Onset and offset characteristics: There is a 2-3 day delay before onset of antihypertensive action after initial patch application, and plasma levels decline gradually over approximately 20 hours after removal 2. This slow decline helps minimize rebound hypertension risk compared to abrupt cessation of oral clonidine 3, 4.
Renal impairment considerations: The half-life increases substantially to up to 41 hours in patients with severe renal impairment 1. Since clonidine has a renal clearance of 102 mL/min and about 40-60% of absorbed drug is recovered unchanged in urine within 24 hours, dose adjustments may be necessary in renal dysfunction 1.
Rebound hypertension: While the transdermal formulation shows little evidence of rebound hypertension after discontinuation 2, abrupt cessation of clonidine therapy (particularly oral forms) can induce hypertensive crisis and must be avoided 3, 4. The patch's gradual decline in plasma levels over 20 hours provides some protection against this complication.